• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Lower; Nonfarm Payrolls Increase More Than Expected

    6/7/24 9:50:25 AM ET
    $BMEA
    $BNED
    $LFLY
    $SCNI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Specialty Stores
    Consumer Discretionary
    Get the next $BMEA alert in real time by email

    U.S. stocks traded lower this morning, following the release of jobs data for May.

    Following the market opening Friday, the Dow traded down 0.22% to 38,799.25 while the NASDAQ fell 0.43% to 17,098.48. The S&P 500 also fell, dropping, 0.31% to 5,336.48.

    Check This Out: Vail Resorts, DocuSign And 3 Stocks To Watch Heading Into Friday

    Leading and Lagging Sectors

    Communication services shares fell by just 0.1% on Friday.

    In trading on Friday, real estate shares dipped by 1.5%.

    Top Headline

    U.S. nonfarm payrolls increased by 272,000 in May, a slowdown from April's 165,000 and far more than the 180,000 increase anticipated by Econoday.

    The unemployment rate inched higher from 3.9% to 4%. Average hourly earnings rose by 4.1% year-over-year, up from 3.9% in April and below the expected 3.9% increase.

    Equities Trading UP
                           

    • Venus Concept Inc. (NASDAQ:VERO) shares shot up 128% to $1.4153 on continued upward momentum after the stock regained Nasdaq compliance.
    • Shares of Trinity Place Holdings Inc. (NYSE:TPHS) got a boost, surging 125% to $0.2769 after declining around 11% on Thursday.
    • Leafly Holdings, Inc. (NASDAQ:LFLY) shares were also up, gaining 77% to $3.56.

    Equities Trading DOWN

    • Biomea Fusion, Inc. (NASDAQ:BMEA) shares dropped 67% to $3.6725 after the United States Food and Drug Administration (FDA) imposed a full clinical hold on its Phase I/II trials for BMF-219, a diabetes treatment.
    • Shares of Barnes & Noble Education, Inc (NYSE:BNED) were down 32% to $0.22 after the company announced final results of rights offering.
    • Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was down, falling 30% to $2.81. Scinai Immunotherapeutics regained compliance with Nasdaq minimum bid price requirement.

    Also Check This Out: Top 3 Energy Stocks That May Fall Off A Cliff In Q2

    Commodities

    In commodity news, oil traded up 0.4% to $75.87 while gold traded down 1.9% at $2,345.20.

    Silver traded down 4.3% to $30.03 on Friday, while copper fell 3.2% to $4.5265.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.3%, Germany's DAX declined 0.8% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index fell 0.3%, while London's FTSE 100 fell 0.4%.

    The Eurozone economy grew by 0.3% on quarter during the first three months of the year, compared to a 0.1% contraction in each of the prior two quarters. The Halifax House Price Index in the UK gained 1.5% year-over-year in May following a 1.1% increase in April.

    French trade deficit increased to €7.6 billion in April, compared to market estimates of €5.4 billion. German trade surplus narrowed to EUR 22.1 billion in April versus a revised EUR 22.2 billion in March. Exports from Germany rose by 1.6% month-over-month to a 14-month high level of EUR 136.5 billion in April, while imports to Germany rose by 2.0% to a 10-month high of EUR 114.5 billion.

    Asia Pacific Markets

    Asian markets closed mixed on Friday, with Japan's Nikkei falling 0.05%, China's Composite Index gaining 0.08%, Hong Kong's Hang Seng Index dipping 0.59% and India's S&P BSE Sensex gaining 2.16%.

    Foreign exchange reserves in Singapore rose to SGD 500.86 billion in May versus SGD 500.30 billion in the prior month, while China’s foreign exchange reserves climbed to $3.23 trillion in May from $3.2 trillion a month ago. China’s trade surplus increased to $82.62 billion in May from $65.55 billion in the year-ago period.

    The index of leading economic indicators in Japan fell to 111.6 in April versus a revised 111.7 in the prior month, while index of coincident economic indicators rose to 115.2 in April from a revised 114.2 in the previous month. The Reserve Bank of India maintained its benchmark policy repo at 6.5% in June.

    Economics

    • U.S. nonfarm payrolls increased by 272,000 in May, a slowdown from April's 165,000 and far more than the 180,000 increase anticipated by Econoday.
    • The unemployment rate inched higher from 3.9% to 4%. Average hourly earnings rose by 4.1% year-over-year, up from 3.9% in April and below the expected 3.9% increase.

    Now Read This: Wall Street’s Most Accurate Analysts Weigh In On 3 Risk Off Stocks Delivering High-Dividend Yields

    Get the next $BMEA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMEA
    $BNED
    $LFLY
    $SCNI

    CompanyDatePrice TargetRatingAnalyst
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    Biomea Fusion Inc.
    $BMEA
    8/28/2025$5.00Buy
    Jefferies
    Biomea Fusion Inc.
    $BMEA
    6/3/2025$7.00Overweight
    Piper Sandler
    Biomea Fusion Inc.
    $BMEA
    10/9/2024$128.00Buy
    Edward Jones
    Biomea Fusion Inc.
    $BMEA
    9/27/2024$18.00Neutral → Buy
    Rodman & Renshaw
    Biomea Fusion Inc.
    $BMEA
    9/27/2024$54.00Hold → Buy
    Truist
    Biomea Fusion Inc.
    $BMEA
    8/29/2024$25.00Overweight
    CapitalOne
    Biomea Fusion Inc.
    $BMEA
    6/11/2024Buy → Hold
    Truist
    More analyst ratings

    $BMEA
    $BNED
    $LFLY
    $SCNI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Erdtmann Rainer M decreased direct ownership by 21% to 572,427 units (SEC Form 5)

    5 - Biomea Fusion, Inc. (0001840439) (Issuer)

    2/6/26 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Erdtmann Rainer M bought $42,999 worth of shares (30,000 units at $1.43), increasing direct ownership by 4% to 723,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/15/25 4:15:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim CEO Hitchcock Michael J.M. bought $99,180 worth of shares (100,000 units at $0.99), increasing direct ownership by 667% to 115,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/4/25 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    $BNED
    $LFLY
    $SCNI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Biomea Fusion with a new price target

    Rodman & Renshaw initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $8.00

    1/13/26 10:18:10 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Biomea Fusion with a new price target

    Jefferies initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $5.00

    8/28/25 8:09:13 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler resumed coverage on Biomea Fusion with a new price target

    Piper Sandler resumed coverage of Biomea Fusion with a rating of Overweight and set a new price target of $7.00

    6/3/25 7:31:50 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    $BNED
    $LFLY
    $SCNI
    SEC Filings

    View All

    SEC Form 15-12G filed by Venus Concept Inc.

    15-12G - Venus Concept Inc. (0001409269) (Filer)

    2/9/26 7:15:41 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $BMEA
    $BNED
    $LFLY
    $SCNI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BMEA
    $BNED
    $LFLY
    $SCNI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Officer Erdtmann Rainer M bought $42,999 worth of shares (30,000 units at $1.43), increasing direct ownership by 4% to 723,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/15/25 4:15:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim CEO Hitchcock Michael J.M. bought $99,180 worth of shares (100,000 units at $0.99), increasing direct ownership by 667% to 115,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/4/25 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Erdtmann Rainer M bought $54,552 worth of shares (50,000 units at $1.09), increasing direct ownership by 8% to 693,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/2/25 4:15:02 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barnes & Noble Education Reports First Half Fiscal 2026 Results and Files Related Quarterly Reports

    BNC First Day Program Revenue Increases 29.0% in 26 weeks ended November 1, 2025 Net Income Improves to $6.7 million Company Reports Total Net Debt of $110.8 million as of November 1, 2025, a $55.1 million Decline Year-Over-Year Reiterates Prior Fiscal 2026 Outlook, including $65-$75 million in Adjusted EBITDA FLORHAM PARK, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Barnes & Noble Education, Inc. (NYSE:BNED), ("Barnes & Noble Education," "BNED," "the Company," "we," "us," "our"), a leading solutions provider for the education industry, today announced that it has filed its Quarterly Report on Form 10-Q for the fiscal quarters ended August 2, 2025 and November 1, 2025. With these filings,

    1/20/26 8:00:00 AM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

    Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes ("T2D") and in T2D patients currently failing glucagon-like peptide-1 ("GLP-1") based therapiesSuccessfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond the validated 12-week regimenAdvancing BMF-650 through clinical development as an oral next-generation GLP-1 receptor agonist candidate designed to deliver effective and patient-friendly metabolic bene

    1/12/26 8:00:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

    JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today announced that its Chief Executive Officer, Amir Reichman, will co-lead a roundtable discussion organized by the Manufacturers Association of Israel during HealthIL Week 2026. The roundtable, titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale," will take place on January 19, 2026 at Expo Tel Aviv. The session is a Manufacturers Association–led roundtable and will be jointly led by Mr.  Reichman together with seni

    1/7/26 7:00:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $BNED
    $LFLY
    $SCNI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Barnes & Noble Education Inc

    SC 13G/A - Barnes & Noble Education, Inc. (0001634117) (Subject)

    11/14/24 6:34:18 PM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Leafly Holdings Inc.

    SC 13G/A - Leafly Holdings, Inc. /DE (0001785592) (Subject)

    11/14/24 5:35:46 PM ET
    $LFLY
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

    SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    11/14/24 4:28:57 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $BNED
    $LFLY
    $SCNI
    Leadership Updates

    Live Leadership Updates

    View All

    Biomea Fusion Appoints Julianne Averill to its Board of Directors

    SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the "Board"), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service. "Julianne is an accomplished leader whose extensive financial, operational, and strategic expertise in the life sciences and digital health industries will be a tremendous asset to Biomea. Her prov

    7/24/25 7:00:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

    Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapyBiomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 202

    5/5/25 4:05:00 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

    Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported

    3/31/25 4:10:00 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    $BNED
    $LFLY
    $SCNI
    Financials

    Live finance-specific insights

    View All

    Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

    Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline, with a 1.8% placebo adjusted mean reduction in HbA1c (Arm B)Type 2 diabetes patients on a GLP-1-based therapy failing to achieve their target HbA1c also showed a clinically meaningful response from only 12 weeks of icovamenib treatment with a mean placebo adjusted HbA1c reduction of 1.8% (Arms A, B, and C combined) at Week 52Icovamenib was generally well tolerated across all dosing arms and demonstrated a favorable safety and tolerability profile through Week 52 Phase II trials

    10/6/25 4:03:07 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

    TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (+1 201-389-0925 for international callers) and provide access code 13756285. A live webcast of the call will also be provided on the investor relations section of the Com

    10/1/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

    JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the six months ended June 30, 2025. Six-Month 2025 Financial Summary  Revenues for the six months ended June 30, 2025, totaled $773 thousand, compared to $284 thousand for the six months ended June 30, 2024. The increase reflects the continued growth of the Company's CDMO business, which gener

    9/2/25 7:30:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care